Background: Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver
disease in the world. Oral administration of synbiotic has been proposed as an effective
treatment of NAFLD because of its modulating effect on the gut flora, which can influence the
gut-liver axis. Objective: The objective was to evaluate the effects of supplementation with
synbiotic on hepatic fibrosis, liver enzymes, and inflammatory markers in patients with
NAFLD. Design: In a randomized, double-blind, placebo-controlled clinical trial conducted …